 |
 Video: What is a Stock Split?
|
|
|
| Nu Skin Enterprises develops and distributes a line of beauty and wellness solutions. Co. develops and distributes products in its primary product categories, personal care products and wellness products, under its Nu Skin and Pharmanex brands, respectively. Co.'s personal care products include its skin care devices. Co.'s skin care devices and related consumables include ageLOC Spa systems and its ageLOC LumiSpa skin treatment and cleansing device. Co.'s wellness products include its LifePak nutritional supplements, ageLOC Youth nutritional supplements and ageLOC TR90 weight management and body shaping system. According to our NUS split history records, NU Skin Enterprises has had 0 splits. | |
|
NU Skin Enterprises (NUS) has 0 splits in our NUS split history database.
Looking at the NUS split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into NU Skin Enterprises shares, starting with a $10,000 purchase of NUS, presented on a split-history-adjusted basis factoring in the complete NUS split history.
Growth of $10,000.00
With Dividends Reinvested
|
| Start date: |
08/17/2012 |
|
| End date: |
08/15/2022 |
|
| Start price/share: |
$40.75 |
|
| End price/share: |
$46.54 |
|
| Starting shares: |
245.40 |
|
| Ending shares: |
325.51 |
|
| Dividends reinvested/share: |
$13.97 |
|
| Total return: |
51.49% |
|
| Average Annual Total Return: |
4.24% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$15,147.61 |
|
| Years: |
10.00 |
|
| |
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/17/2012 |
|
| End date: |
08/15/2022 |
|
| Start price/share: |
$40.75 |
|
| End price/share: |
$46.54 |
|
| Dividends collected/share: |
$13.97 |
|
| Total return: |
48.49% |
|
| Average Annual Total Return: |
4.03% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$14,845.20 |
|
| Years: |
10.00 |
|
|
|
|
|
